News

Spineart today announced it has completed 1,000 Scarlet AC-T surgeries in the US. Scarlet AC-T is the first stand-alone cervical device offered by Spineart. The titanium cage, secured with titanium screws, is inserted flush to vertebral bodies thus reducing potential risks associated with dysphagia and adjacent-level ossification. With lordotic and anatomic profiles, 2 footprints, and multiple cage heights Scarlet, AC-T allows surgeons to address variable patient anatomy while providing optimal fit between endplates. As with all of Spineart’s ever-expanding spine portfolio, the Scarlet AC-T system is comprised of sterile implants and one compact instrument set.

Spineart has strengthened its production capacity with the acquisition of Alpes-CN, a recognized expert in spinal implant manufacturing. This key step in Spineart’s expansion will support the Company’s rapid growth while maintaining the highest level of customer service.

Since the first half of 2016, Spineart has maintained a steady growth rate of 25.6% worldwide. Driving these results is a 35.7% increase in US sales, a 25.1% increase in direct country sales, as well as several new product launches, including the Company’s proprietary Ti-Life Technology, a 3D-printed macroporous scaffold that mimics trabecular bone.

Geneva, September 1st 2007. Spineart’s direct sales team has already garnered an 8% market share, after less than two years of commercialization of its products, thanks to its closeness and close collaboration with some of the country’s leading spinal surgeons. Spineart ‘s goal is to reach a 10% market share by end 2008.

Spineart announces the publication of Arthroplasty with the Baguera®C Cervical Disc Prosthesis: A Review of the Scientific Background, Clinical and Radiographic Evidences(1) in the Journal of Spine & Neurosurgery

The authors discussed peer-reviewed or published literature studying the Baguera®C cervical disc prosthesis clinical and radiological results. The goal of the review was to evaluate the clinical outcomes of cervical disc replacement with Baguera®C and discuss these in comparison with the results of other prosthesis in the literature.

The review reported the results of three case series evaluating the safety and performance of Baguera®C over an observational period of two years.

The authors concluded that cervical disc replacement with Baguera®C is a safe and effective procedure for the treatment of radiculopathy due to soft disc herniation and/or moderate uncarthrosis on 1 or 2 levels. The results showed that Baguera®C had limited or no influence on the biomechanics of adjacent levels. The rate of heterotopic ossification tended to be lower compared to other cervical disc prosthesis published in the literature.

So far, more than 15’000 BAGUERA®C disc prosthesis have been implanted worldwide. The first surgery was performed in France in January 2007.24

Spineart today announces that it secured a EUR 30 million investment from Gimv[1]. These proceeds will be used to reinforce the company’s sales organization and processes, for further geographical expansion in selective markets such as the US and Europe, as well as for continued development of innovative and disruptive products.

“Gimv is the partner we need to reach the next level. Its Health & Care team’s experience in accompanying fast growing companies will help to reach Spineart’s ambitious goals. Therefore, we are very pleased to have them on board and are excited to write together the next chapter in Spineart’s history,” said Jérôme Levieux and Stéphane Mugnier-Jabob, co-founders and co-CEOs of Spineart.

Gimv is an investment company with over three decades experience in private equity and venture capital, listed on Euronext Brussels. The company identifies entrepreneurial and innovative companies with high-growth potential and supports them in their transformation into market leaders, and currently manages around 1.8 billion EUR of investments.

Peter Byloos, Partner in Gimv’s Health & Care team, comments: “Spine surgery is an attractive global market offering plenty of room for challengers such as Spineart. Next to its broad product portfolio and recognized European brand, the company differentiates itself by a strong focus on product innovation and full R&D pipeline. We look forward to share our expertise in the field of Building Companies and International Operations with Spineart’s experienced and committed leadership team”.

More information on Gimv can be found on www.gimv.com.

[1] Joint-investment by Gimv and the Gimv Health & Care Fund

Spineart SA, announces today, that they will market directly its product range in Australia through the newly established entity Spineart Australia Pty Ltd.

Spineart Australia will cooperate with Sportmedtech, an Australian incorporated company located in Melbourne, VIC.

Sportmedtech team has over 10 years of experience in spine & orthobiologics in Australia with established connections to local surgeons and will be instrumental to promote Spineart’s comprehensive portfolio in the fields of MIS surgery, motion preservations, fusion, biologics and fracture treatment.

The Australian spine market, valued at approx. USD 230 million is presenting a growth opportunity for Spineart SA.

Spineart’s range associated to Sportmedtech’s connections and market knowledge is the right association to success in the challenging Australia market place.